Chapter

References:

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

1. Breast Cancer

   "U.S. Food and Drug Administration. \"FDA Grants Accelerated Approval to a New Breast Cancer Treatment.\" Sept. 4,"

2. Hyrnuo Approval

   "Healio. \"FDA OKs Accelerated Approval to Frontline Hyrnuo for Non-Small Cell Lung Cancer.\" Sept. 9,"

3. Ameluz Approval

   "Biofrontera. \"Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma.\" GlobeNewswire, Sept. 14,"

4. Bexlutry Approval

   "Curium. \"Curium Announces FDA Approval of Bexlutry Lutetium Lu 177 Dotatate Injection for Adults With SSTR-Positive GEP-NETs.\" Sept. 14,"

5. Imlunestrant Approval

   "The ASCO Post. \"FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.\" Sept. 18,"

6. Bravnetsa Approval

   "Cancer Therapy Advisor. \"FDA Approves Bravnetsa as Equivalent to Lutathera for GEP-NETs.\" Sept. 25,"